Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 5.

Journal Article

Al-Sawaf, O., Bahlo, J., Fischer, K., Herling, C., Hoechstetter, M., Fink, A., von Tresckow, J., Langerbeins, P., Cramer, P., Stilgenbauer, S., Wendtner, C., Eichhorst, B., Hallek, M. and Goede, V. (2017). CHARACTERISTICS, TREATMENT, AND OUTCOMES OF >= 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP. Haematologica, 102. S. 421 - 422. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Al-Sawaf, O., Robrecht, S., Fink, A., Ritgen, M., Johansson, P., Staber, P., Jaeger, U., Niemann, C., Pallasch, C., Kreuzer, K., Stilgenbauer, S., Fischer, K., Wendtner, C., Hallek, M. and Eichhorst, B. (2020). The CLL-RT1 trial: A multi-center phase-2 trial to evaluate the efficacy and safety of zanubrutinib, a BTK inhibitor, plus tislelizumab, a PD-1 inhibitor, for treatment of patients with Richter Transformation. Oncol. Res. Treat., 43 (SUPPL 4). S. 73 - 74. BASEL: KARGER. ISSN 2296-5262

Loeschcke, K., Fink, A., Bahlo, J., Westermann, A., Zey, A., Fischer, K., Wendtner, C. M., Noesslinger, T., Ghia, P., Bosch, F., Kater, A. P., Kreuzer, K. A., Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2014). CENTRAL SCREENING ENABLES IDENTIFICATION OF HIGH RISK CLL PATIETNS FOR LENALIDOMIDE MAINTENANCE THERAPY WITHIN THE CLLM1 TRIAL OF THE GERMAN CLL STUDY GROUP. Haematologica, 99. S. 587 - 589. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Tausch, E., Landau, D., Taylor-Weiner, A., Stewart, C., Reiter, J., Bahlo, J., Kluth, S., Bozic, I., Lawrence, M., Boettcher, S., Cibulskis, K., Mertens, D., Sougnez, C., Rosenberg, M., Hess, J., Carter, S., Edelmann, J., Kless, S., Fink, A., Fischer, K., Ritgen, M., Kneba, M., Gabriel, S., Lander, E., Nowak, M., Doehner, H., Hallek, M., Neuberg, D., Getz, G., Stilgenbauer, S. and Wu, C. (2015). WHOLE EXOME SEQUENCING OF 278 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS FROM THE CLL8 TRIAL UNCOVERS DRIVER MUTATIONS WITH CLINICAL IMPACT AND THEIR EVOLUTIONARY HISTORY IN CANCER PATHOGENESIS. Haematologica, 100. S. 335 - 337. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Westermann, A., Fink, A., Zey, A., Wesselmann, J. S., Busch, R., Fischer, K., Wendtner, C., Kreuzer, K-A, Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2014). Screening supported by a central review allows a precise selection of the population for maintenance therapy within the CLLM1 trial of the German CLL Study Group. Oncol. Res. Treat., 37. S. 85 - 86. BASEL: KARGER. ISSN 2296-5262

This list was generated on Tue Nov 26 06:08:31 2024 CET.